Navigation Links
AFFiRiS Begins Development of a Parkinson's Vaccine
Date:12/11/2008

VIENNA, Austria, December 11 /PRNewswire/ -- AFFiRiS has started pre-clinical development of a Parkinson's vaccine. The vaccine, known as PD01, can be used to target a specific protein that is closely associated with the causes of this degenerative neurological disease. Excellent product candidates from discovery studies have prompted the company to file a patent application and proceed immediately with development. Similarly positive results from external assessments impelled the Austrian Research Promotion Agency (FFG) to provide considerable financial funding for the project. The vaccine is based on the company's AFFITOME technology, which, among other things, has already been used to develop two Alzheimer's vaccines, which are currently both in phase I clinical testing.

AFFiRiS, based in Vienna, Austria, today announced the start of the pre-clinical development of its first Parkinson's vaccine PD01. The vaccine will be investigated for efficacy ("proof of concept") in Parkinson models. On successful conclusion of this preclinical evaluation, initial clinical testing could start in 2010/11. The Parkinson's vaccine specifically targets the alpha-synuclein (alpha-syn) protein, which is considered to be a key contributory element in Parkinson's disease.

Although all details of the disease are not yet fully understood, there is clear scientific evidence that the concentration and enrichment of alpha-syn in the brain are contributing factors in the progression of Parkinson's disease. Therefore, reducing the alpha-syn burden in the brain should have a positive impact on the course of the disease - a hypothesis that was recently confirmed by the results of U.S. researchers working on animal models.

The Parkinson's vaccine from AFFiRiS has been developed to delivery efficacy in combination with an excellent safety profile, as Dr. Walter Schmidt, CEO of AFFiRiS, explains: "Alpha-syn is an attractive targ
'/>"/>

SOURCE AFFiRiS GmbH
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. AFFiRiS: Milestone Reached in Clinical Trial of Alzheimers Vaccine
2. Halozyme Therapeutics Begins Phase 1 Clinical Trial of Bisphosphonate Administered With rHuPH20 Enzyme
3. Halozyme Therapeutics Announces Roche Begins Phase 1 Clinical Trial and Selects Fourth Exclusive Biologic Target
4. Genaera Begins Phase 1b Trial of Trodusquemine (MSI-1436) in Overweight and Obese Type 2 Diabetics
5. Patient Recruitment Begins in India for Phase 3 Diabetes Trial
6. Lotus Pharmaceuticals, Inc.s New Drug Laevo-Bambutero Begins Evaluation for Clinical Trials
7. Second Pivotal Phase 3 Trial In Cystic Fibrosis Begins
8. Light Sciences Oncology Begins Clinical Trials of Litx Therapy in Patients with Enlarged Prostate
9. Catalyst Pharmaceutical Partners, Inc. Begins Enrollment for U.S. Phase II Clinical Trial of CPP-109 in Patients with Methamphetamine Addiction
10. Champions Biotechnology Begins Preclinical Development of Its Lead Oncology Drug Candidate
11. European Enrollment Begins in Pivotal Phase 3 Trial of Novel Combination Medicine Developed by Cogentus Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... Ala. , Aug. 19, 2014  The Alabama Supreme ... that patients can sue drug makers who mislead doctors into ... harmful side‑effects.  The case is Weeks v. Wyeth, and the ... makers in that same case last year. Heninger Garrison Davis ... represent the patient in the case, Danny Weeks . ...
(Date:8/19/2014)... DUBLIN , Aug. 19, 2014 ... the "Pharmaceutical Contract Manufacturing - Global Strategic Business ... This report analyzes the worldwide markets for Pharmaceutical Contract ... Injectables (Injections, Vials, and IV solutions), Solid Dosage Forms ... (Syrups, Suspensions, Gels, Creams & Ointments). The ...
(Date:8/19/2014)... , Aug. 19, 2014  AVIA – a ... task on the biggest problems in healthcare ­– announces ... Northern California , as the most recent addition ... Health will participate in AVIA,s inaugural cohort focused helping ... care and transparency among a patient,s providers so they ...
Breaking Medicine Technology:Heninger Garrison Davis Clients To Get Their Day in Court Against Brand Drug Companies 2Heninger Garrison Davis Clients To Get Their Day in Court Against Brand Drug Companies 3Heninger Garrison Davis Clients To Get Their Day in Court Against Brand Drug Companies 4Global Pharmaceutical Contract Manufacturing - Strategic Business Report 2014 2AVIA and Sutter Health Join Forces to Address Healthcare's Most Pressing Challenges 2
... Sept. 23, 2011 Henry Ford Hospital became the third ... Stimulation (DBS) procedure inside an Intraoperative Magnetic Resonance Imaging scanner, ... the neurosurgical toolbox," says Jason M. Schwalb, M.D., Director of ... "Although awake surgery with brain mapping is still ...
... Science, Inc., creators of the Basis™ B1 band, today announced ... and gaming luminaries including Kevin Colleran, Charles and Kai Huang, ... Chris Verplaetse to join the company,s executive team as vice ... launched later this year, the Basis B1 band is the ...
Cached Medicine Technology:DBS Operation for Parkinson's Disease Performed Inside iMRI 2Basis Announces Advisory Board Members from Medicine, Gaming and Social Networking 2Basis Announces Advisory Board Members from Medicine, Gaming and Social Networking 3
(Date:8/20/2014)... 2014 The National Association of ... million Science Education Partnership Award (SEPA) grant from ... collaborative project with the Hispanic Communications Network (HCN) ... This collaborative NIH R25 program has been established ... diversity among health professionals by recruiting and interviewing ...
(Date:8/20/2014)... August 20, 2014 New Jersey’s Medical ... of an estimated tens of thousands of patients in ... Bill A3525—a bill that would expand the list of ... own cannabis—earlier this summer by State Assemblywoman Linda Stender, ... quality marijuana is growing. , To help fill the ...
(Date:8/20/2014)... Verndale is pleased to announce their ... exclusive list ranking the fastest-growing private companies in America. ... their yearly percentage revenue growth over a three-year period. ... Inc. 5000 list where it ranked number 2,855. , ... clients a wide range of digital marketing services including ...
(Date:8/20/2014)... 2014 B. E. Smith, the only ... has been retained to lead a national chief ... System in Hermiston, Ore. The top executive search ... has recently placed more than 900 healthcare executives into ... a progressive, not-for-profit healthcare organization serving a population of ...
(Date:8/20/2014)... 2014 Biosimilars, which are similar ... through an abbreviated process, could reap billions in ... Information Services, Inc.’s (AIS) Specialty Pharmacy News offers ... the Food and Drug Administration’s (FDA) recent acceptance ... approval. , Drugmaker Sandoz said July 24 that ...
Breaking Medicine News(10 mins):Health News:National Association of Hispanic Nurses (NAHN) Receives Five-Year Federal Grant from the National Institutes of Health (NIH) 2Health News:National Association of Hispanic Nurses (NAHN) Receives Five-Year Federal Grant from the National Institutes of Health (NIH) 3Health News:Oaksterdam University to Host Four-Day Educational Marijuana Horticultural Seminar Aug 23-26; Training Fills Information Gap for Medical Marijuana Caregivers and Patients 2Health News:Oaksterdam University to Host Four-Day Educational Marijuana Horticultural Seminar Aug 23-26; Training Fills Information Gap for Medical Marijuana Caregivers and Patients 3Health News:For the 8th Time, Verndale Has Been Honored on the Inc. 5000 List 2Health News:Good Shepherd Health Care System Retains B. E. Smith to Recruit New COO 2Health News:Good Shepherd Health Care System Retains B. E. Smith to Recruit New COO 3Health News:AIS Newsletter Tracks Latest Developments in Biosimilars Market as FDA Accepts First Application 2Health News:AIS Newsletter Tracks Latest Developments in Biosimilars Market as FDA Accepts First Application 3
... TUESDAY, Jan. 4 (HealthDay News) -- President Barack Obama ... gives the U.S. Food and Drug Administration unprecedented powers ... The Food Safety Modernization Act, first passed by the ... represents the first significant strengthening of the nation,s food ...
... (HealthDay News) -- Levels of schooling may affect treatment and ... called acute ST-segment elevation myocardial infarction (STEMI), a new study ... attack, STEMI occurs when the coronary artery is totally blocked, ... In the new study, Dr. Rajendra H. Mehta, from ...
... N.C. A tiny light source and sensors at the ... to identify pre-cancerous cells in the lining of the esophagus. ... tested on patients during a clinical trial at the University ... promise of being a less invasive method for testing patients ...
... for the 2013 America,s Cup has been announced, a study ... smooth sailing. The study was published recently in the journal ... survey completed by sailors, researchers at Rhode Island Hospital have ... two types of boats -- dinghies (small boats with crews ...
... , TUESDAY, Jan. 4 (HealthDay News) -- Elderly people ... dementia, researchers have found. The new study included more ... dental examination and a psychiatric assessment. Compared with participants who ... or no teeth were much more likely to have experienced ...
... patients with osteoarthritis (OA) are likely not following standard ... Researchers noted physicians were prescribing medications for pain and ... weight loss plans or exercise programs to OA patients. ... January 2011 issue of Arthritis Care & Research ...
Cached Medicine News:Health News:Obama to Sign Bill to Improve U.S. Food Safety 2Health News:Obama to Sign Bill to Improve U.S. Food Safety 3Health News:Higher Education May Benefit Some Heart Attack Patients 2Health News:Detecting esophageal cancer with light 2Health News:Watch out for that boom 2Health News:Watch out for that boom 3Health News:Clinical practitioners not adhering to evidence-based guidelines for osteoarthritis 2Health News:Clinical practitioners not adhering to evidence-based guidelines for osteoarthritis 3
The NOW Flu A test is the most frequently adopted rapid flu test on the market today. Testing could not be easier and the results are available in 15 minutes. Now you can focus on the results and tre...
... The Shandon Finesse ME+ is designed ... in todays busy laboratories by being one ... microtomes offered today. Excellent for routine wax ... Finesse ME + provides high quality sections ...
The Pach IV is the premier product for cornea thickness measurement in conjunction with Glaucoma screening....
The Shandon Linistat Linear Stainer is a compact answer to H&E frozen section protocols, with a footprint that fits on top of most cryostas to streamline workflow during frozen sectioning....
Medicine Products: